Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.6 USD | 0.00% | 0.00% | +2.56% |
May. 13 | Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 06 | Top Premarket Gainers | MT |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 309 | 633.5 | 198.8 | 220.1 | - | - |
Enterprise Value (EV) 1 | 309 | 633.5 | 198.8 | 220.1 | 220.1 | 220.1 |
P/E ratio | -2.42 x | -13.6 x | -4.73 x | -4.17 x | -3.67 x | -8.68 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | 21.6 x | 2.52 x |
EV / Revenue | - | - | - | - | 21.6 x | 2.52 x |
EV / EBITDA | -3.8 x | -15.5 x | -4 x | -3.79 x | -3.46 x | -3.55 x |
EV / FCF | -14,336,714 x | - | - | - | - | - |
FCF Yield | -0% | - | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 97,472 | 125,938 | 127,455 | 137,589 | - | - |
Reference price 2 | 3.170 | 5.030 | 1.560 | 1.600 | 1.600 | 1.600 |
Announcement Date | 3/18/22 | 3/15/23 | 3/21/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | 10.17 | 87.2 |
EBITDA 1 | - | -81.32 | -40.87 | -49.66 | -58.16 | -63.62 | -61.96 |
EBIT 1 | - | -81.88 | -41.66 | -50.36 | -57.57 | -71.5 | -38.35 |
Operating Margin | - | - | - | - | - | -702.99% | -43.98% |
Earnings before Tax (EBT) 1 | -29.47 | -82.18 | -39.22 | -42.49 | -53.16 | -69.07 | -35.18 |
Net income 1 | -29.5 | -82.18 | -39.22 | -42.49 | -53.16 | -71.23 | -31.72 |
Net margin | - | - | - | - | - | -700.29% | -36.38% |
EPS 2 | - | -1.310 | -0.3700 | -0.3300 | -0.3840 | -0.4357 | -0.1843 |
Free Cash Flow | - | -21.55 | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 3/5/21 | 3/18/22 | 3/15/23 | 3/21/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA 1 | -12.88 | -7.017 | -8.767 | -12.4 | -12.69 | -9.517 | -13.16 | -11.76 | -15.23 | -12.62 | -13.98 | -15.06 | -16.4 | -14.67 | -14.95 |
EBIT 1 | -13 | -7.182 | -8.987 | -12.6 | -12.89 | -9.711 | -13.34 | -11.93 | -15.39 | -12.77 | -13.82 | -13.95 | -15.42 | -14.82 | -15.11 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -12.99 | -7.162 | -8.494 | -11.98 | -11.59 | -7.837 | -11.28 | -9.964 | -13.42 | -10.79 | -12.93 | -13.47 | -15.26 | -14.82 | -15.11 |
Net income 1 | -12.98 | -7.162 | -8.494 | -11.98 | -11.59 | -7.837 | -11.28 | -9.964 | -13.42 | -10.79 | -12.93 | -13.47 | -15.26 | -14.82 | -15.11 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.0500 | -0.0700 | -0.0800 | -0.1200 | -0.1000 | -0.0600 | -0.0900 | -0.0800 | -0.1100 | -0.0800 | -0.0940 | -0.0980 | -0.1060 | -0.0900 | -0.0900 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/18/22 | 5/9/22 | 8/1/22 | 11/9/22 | 3/15/23 | 5/4/23 | 8/3/23 | 11/9/23 | 3/21/24 | 5/13/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | -21.6 | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | 1.89 | 0.21 | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 3/5/21 | 3/18/22 | 3/15/23 | 3/21/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.56% | 220M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- CMPX Stock
- Financials Compass Therapeutics, Inc.